Abstract:Rationale: SUMOylation regulates a plethora of biological processes, and its inhibitors are currently under investigation in clinical trials as anticancer agents. Thus, identifying new targets with site-specific SUMOylation and defining their biological functions will not only provide new mechanistic insights into the SUMOylation signaling but also open an avenue for developing new strategy for cancer therapy. MORC family CW-type zinc finger 2 (MORC2) is a newly identified chromatin-remodeling enzyme with an emerging role in the DNA damage response (DDR), but its regulatory mechanism remains enigmatic. Methods: In vivo and in vitro SUMOylation assays were used to determine the SUMOylation levels of MORC2. Overexpression and knockdown of SUMO-associated enzymes were used to detect their effects on MORC2 SUMOylation. The effect of dynamic MORC2 SUMOylation on the sensitivity of breast cancer cells to chemotherapeutic drugs was examined through in vitro and in vivo functional assays. Immunoprecipitation, GST pull-down, MNase, and chromatin segregation assays were used to explore the underlying mechanisms. Results: Here, we report that MORC2 is modified by small ubiquitin-like modifier 1 (SUMO1) and SUMO2/3 at lysine 767 (K767) in a SUMO-interacting motif dependent manner. MORC2 SUMOylation is induced by SUMO E3 ligase tripartite motif containing 28 (TRIM28) and reversed by deSUMOylase sentrin-specific protease 1 (SENP1). Intriguingly, SUMOylation of MORC2 is decreased at the early stage of DNA damage induced by chemotherapeutic drugs that attenuate the interaction of MORC2 with TRIM28. MORC2 deSUMOylation induces transient chromatin relaxation to enable efficient DNA repair. At the relatively late stage of DNA damage, MORC2 SUMOylation is restored, and SUMOylated MORC2 interacts with protein kinase CSK21 (casein kinase II subunit alpha), which in turn phosphorylates DNA-PKcs (DNA-dependent protein kinase catalytic subunit), thus promoting DNA repair. Notably, expression of a SUMOylation-deficient mutant MORC2 or administration of SUMO inhibitor enhances the sensitivity of breast cancer cells to DNA-damaging chemotherapeutic drugs. Conclusions: Collectively, these findings uncover a novel regulatory mechanism of MORC2 by SUMOylation and reveal the intricate dynamics of MORC2 SUMOylation important for proper DDR. We also propose a promising strategy to sensitize MORC2-driven breast tumors to chemotherapeutic drugs by inhibition of the SUMO pathway.

Proteome-wide Analysis of SUMO2 Targets in Response to Pathological DNA Replication Stress in Human Cells.

Regulation of SUMO2 Target Proteins by the Proteasome in Human Cells Exposed to Replication Stress

SUMOylation of HNRNPA2B1 Modulates RPA Dynamics During Unperturbed Replication and Genotoxic Stress Responses.

Functional Characterization of TIP60 Sumoylation in UV-irradiated DNA Damage Response.

Mechanism and function of DNA replication‐independent DNA‐protein crosslink repair via the SUMO‐RNF4 pathway

Sumoylation Influences DNA Break Repair Partly by Increasing the Solubility of a Conserved End Resection Protein.

SUMO paralogue–specific functions revealed through systematic analysis of human knockout cell lines and gene expression data

The Deubiquitinase Usp36 Regulates Dna Replication Stress And Confers Therapeutic Resistance Through Primpol Stabilization

SUMOylation Stabilizes Hssb1 and Enhances the Recruitment of NBS1 to DNA Damage Sites

SUMOylation mediates CtIP’s functions in DNA end resection and replication fork protection

SUMO and the robustness of cancer

SUMO is a pervasive regulator of meiosis

SUMO-1 Modification of FEN1 Facilitates Its Interaction with Rad9-Rad1-Hus1 to Counteract DNA Replication Stress

Concerted SUMO-targeted ubiquitin ligase activities of TOPORS and RNF4 are essential for stress management and cell proliferation

Site-specific inhibition of the small ubiquitin-like modifier (SUMO)-conjugating enzyme Ubc9 selectively impairs SUMO chain formation

Abstract 5393: Characterization of small ubiquitin-like modifier (SUMO) protein complex expression in human cancer cells to identify novel therapeutic targets

Replisome Proximal Protein Associations and Dynamic Proteomic Changes at Stalled Replication Forks

DNA Damage Response and SUMO Modification

NMR metabolomic profiling reveals new roles of SUMOylation in DNA damage response

Multifaceted roles of SUMO in DNA metabolism

Dynamic SUMOylation of MORC2 orchestrates chromatin remodelling and DNA repair in response to DNA damage and drives chemoresistance in breast cancer